Document Detail


Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
MedLine Citation:
PMID:  18811891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Despite the introduction of new drugs that have changed the course of pulmonary arterial hypertension (PAH), some patients are still refractory to treatment and deteriorate rapidly. Long-acting phosphodiesterase-5 inhibitors are a new class of drugs that are effective in PAH. This prospective study assessed the potential of combination therapy with prostacyclin and tadalafil for treatment of severe PAH. We report four cases of severe PAH that deteriorated despite prostacyclin therapy. Two patients had Eisenmenger syndrome, one had pulmonary hypertension associated with scleroderma and one had histiocytosis X. All were treated with tadalafil, 10-20 mg once daily, in addition to prostacyclin. After 3 months of treatment, all patients improved clinically, with an increase in mean 6MWD from 214 to 272 m. In three patients, the New York Heart Association functional class decreased from IV to III. Echocardiograms showed no significant changes in pulmonary arterial pressure. Although this study was limited by the small sample size, it suggests that tadalafil in combination with prostacyclin is an effective treatment for severe PAH. Tadalafil may be beneficial for the treatment of patients with advanced disease.
Authors:
Daniele Bendayan; David Shitrit; Mordechai R Kramer
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Respirology (Carlton, Vic.)     Volume:  13     ISSN:  1440-1843     ISO Abbreviation:  Respirology     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-09-24     Completed Date:  2009-02-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9616368     Medline TA:  Respirology     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  916-8     Citation Subset:  IM    
Affiliation:
Pulmonary Institute, Rabin Medical Center, Beilinson Campus, Petah Tiqwa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antihypertensive Agents / therapeutic use*
Carbolines / therapeutic use*
Drug Therapy, Combination
Eisenmenger Complex / complications
Epoprostenol / therapeutic use*
Female
Humans
Hypertension, Pulmonary / drug therapy*,  etiology
Middle Aged
Phosphodiesterase Inhibitors / therapeutic use*
Pilot Projects
Prospective Studies
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Carbolines; 0/Phosphodiesterase Inhibitors; 0/tadalafil; 35121-78-9/Epoprostenol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical characteristics and efficacy of bronchoscopic intervention for tracheobronchial leiomyoma.
Next Document:  Pulmonary hypertension responding to hyperthyroidism treatment.